PPBT · Purple Biotech Ltd.

This disclosure represents a HIGH-materiality event because it presents the first peer-validated, multi-tumor-type preclinical evidence demonstrating consistent, potent anti-tumor activity of IM1240 across clinically relevant, treatment-resistant solid tumors — including head and neck, bladder, NSCLC, and triple-negative breast cancer models. Critically, the data were generated independently in Dr. Amir Horowitz’s lab at Mount Sinai, lending scientific credibility beyond internal research. The mechanistic validation — loss of activity upon NKG2A-binding domain mutation — confirms the functional necessity of the NKG2A arm, distinguishing IM1240 from conventional CD3-engagers and supporting its dual T/NK cell engagement rationale. The induction of tertiary lymphoid structures (TLS) in NSCLC explants is particularly significant: TLS are histopathological biomarkers strongly associated with durable clinical responses and survival benefit in multiple immunotherapy trials, suggesting IM1240 may drive biologically meaningful immune remodeling rather than transient cytotoxicity. While no clinical trial initiation date or regulatory pathway is disclosed, the breadth of responsive tumor types and resistance profiles implies potential for accelerated development in biomarker-agnostic or biomarker-enriched populations. However, the absence of pharmacokinetic, safety, or dosing data — and the preclinical-only status of both IM1240 and IM1305 — means clinical translation remains unproven. The continued reliance on external partnering or investment for CM24 and NT219 further underscores near-term capital and strategic execution risk.